Group CEO and Founder

Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets

Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)

Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits

FDA nod for Cycle Pharma’s Harliku for alkaptonuria

National Account Manager Payers

Cycle Pharmaceuticals is dedicated to ensuring patients receive the treatments they need. The National Account Manager, Payers will develop and execute market access strategies, engage with payers and PBMs, and oversee pricing and reimbursement initiatives to optimize access for Cycle’s products.

Sign up with Google

Sign in with Google